Allergan’s Forest to face jury in antitrust suit over Alzheimer drug
15-06-2021
AbbVie slammed over ‘drip feed’ of Imbruvica patents
20-07-2020
Health campaigners call for greater checks on AbbVie/Allergan merger
20-02-2020
Piotr Swat / Shutterstock.com
Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase), in a development meant to satisfy antitrust regulations in the US.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Allergan, drug, divestments, biopharmaceutical, pharmaceutical, brazikumab, Zenpep, antitrust, regulations
